Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake

Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake

Hypogonadism

TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.

TFG capsules (200 mg /capsule)

During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.

Placebo oral capsule

Department of Urology, Pusan National University Hospital

Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS

Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial

Hyun Jun Park

Associate Professor

Pusan National University Hospital

Venous Thromboembolism

Neoplasms

weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose

low molecular weight heparin

Target INR between 2-3. Any type allowed, if approved for use in that country.

vitamin K antagonists

George Washington University

University Health Network

Medical Clinic Dresden University

Ospedali Riuniti

Hospital d'Annunziata

Ospedaliera di Padova

Arcispedale Santa Maria Nuova (ASMN)

Ospedale di Circolo

Flevoziekenhuis

Academic Medical Centre (AMC)

Slotervaart Hospital

Reinier de Graaf Groep

Medisch Spectrum Twente

University Medical Centre Groningen (UMCG)

Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

Pieter W. Kamphuisen, MD PhD

Prof

University Medical Center Groningen

A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.
B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.
C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent

A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.
B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent

Cancer

Thrombosis

Angina Pectoris

Shaare Zedek Medicla Center

Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients

Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients Compared to Patients With Unstable Angina Pectoris; The Possible Role of Heparanase

yair plesser

study manager

Shaare Zedek Medical Center

Gastric Cancer

Esophageal Cancer

Tumors

Epirubicin

Carboplatin

Capecitabine

Cross Cancer Institute

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Combined Phase I/II Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

AHS Cancer Control Alberta

coumarin

syöpä

neoplasms

coumarin/syöpä

Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS

Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Täydellisin lääketieteellinen tietokanta tieteen tukemana